Orchid receives USFDA node for new drug

The company has received approval from the US Food and Drug Administration for Divalproex Sodium Delayed, Orchid Chemicals & Pharmaceuticals said in a filing to the Bombay Stock Exchange.

Mania is a severe medical condition characterised by extremely elevated mood, energy, unusual thought patterns and sometimes psychosis. Divalproex Sodium Delayed-release tablets will be available in strengths 125 mg, 250 mg and 500 mg, the filing added.

Shares of the company were trading at Rs84, up 3% on the BSE.

Milestone Alert!
Livemint tops charts as the fastest growing news website in the world 🌏 Click here to know more.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!